?>
Contact us
Follow Us
About Us
Members
Executive Director
Why Biosimilars
The Issue
Our Solutions
Biosimilars 101
Foundations
Core Principles
FDA Regulatory Tenets
Biosimilars FAQs
Future Evolution of Biosimilar Development
Approved Biosimilars
Advocacy
Our Action
Tools
News
Resources
Get Involved
Partners
News
Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
News
January 11, 2017
Katie Quinn
Biosimilars Forum Statement Regarding the CMS’ Treatment of Biosimilars Under the Medicaid Drug Rebate Program
News
November 1, 2016
Katie Quinn
Awareness of Biosimilars Among U.S. Specialty Physicians is High but New Survey Identifies Five Major Knowledge Gaps
News
October 20, 2016
Katie Quinn
Biosimilars Forum Submits comments on FDA Biosimilar Biological Product Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022
News
September 16, 2016
Katie Quinn
Biosimilars Forum Applauds Outcome of BsUFA Negotiations; Pleased to Have Played Important Role in Decision-Making
News
June 3, 2016
Katie Quinn
Biosimilars Forum Submits Comments in Response to FDA Draft Industry Guidance on Labeling for Biosimilar Products
News
March 31, 2016
Katie Quinn
Biosimilars Forum Issues Statement on FDA Draft Industry Guidance on Labeling for Biosimilar Products
News
March 16, 2016
Katie Quinn
Biosimilars Forum Issues Statement on Proposed Part B Drug Payment Model
News
February 9, 2016
Katie Quinn
Biosimilars Forum Statement: FDA Arthritis Advisory Committee Meeting for Biosimilar to Remicade (Infliximab), Submitted by Celltrion, Inc.
News
February 4, 2016
Katie Quinn
Biosimilars Forum Issues Statement Regarding House Energy & Commerce, Subcommittee on Health Biosimilars Hearing, Launch of New Biosimilars Education Initiative
News
February 1, 2016
Katie Quinn
Biosimilars Forum Launches “Partnership for Biosimilars Education and Access”
Prev page
16
17
18
19
20
Next page